John Mcqueen
Glasgow, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 09, 2026
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: March 25, 2024
Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Journal: Nature communications
Published: September 26, 2023
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Journal: Nature communications
Published: October 21, 2022
SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS).
Journal: Clinical colorectal cancer
Published: March 21, 2022
Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis.
Journal: Clinical colorectal cancer
Published: February 03, 2021
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Journal: Health technology assessment (Winchester, England)
Published: December 20, 2019
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Journal: Nature communications
Published: October 31, 2018
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
Journal: Journal of the National Cancer Institute
Published: June 10, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
Journal: British journal of cancer
Published: April 06, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Journal: The Lancet. Oncology
Published: July 09, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026